Syngen Biotech Co.,Ltd. (TPEX:8279)
Taiwan · Delayed Price · Currency is TWD 113.00
-2.50 (-2.16%)
Mar 4, 2026, 10:48 AM CST
Syngen Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 271.59 | 240.21 | 274.83 | 321.24 | 237.77 |
Depreciation & Amortization | 121.33 | 114.41 | 99.29 | 86.31 | 81.27 |
Other Amortization | - | 0.27 | 0.18 | 0.19 | 0.13 |
Loss (Gain) From Sale of Assets | 0.15 | 0.15 | 0.28 | 0.21 | 0.63 |
Asset Writedown & Restructuring Costs | 0.4 | - | - | - | 1.81 |
Loss (Gain) From Sale of Investments | -0.3 | 0.49 | -0.02 | -0.21 | -0.98 |
Loss (Gain) on Equity Investments | -8.09 | 5.32 | -36.08 | -26.64 | -14.81 |
Provision & Write-off of Bad Debts | -3.02 | 6.92 | -8.58 | 17.82 | 0.33 |
Other Operating Activities | 1.36 | -5.37 | 12.24 | 36.67 | 33.37 |
Change in Accounts Receivable | -28.24 | -22.29 | 90.02 | -101.12 | -13.1 |
Change in Inventory | -29.42 | -1.19 | 1.98 | -98.11 | -41.33 |
Change in Accounts Payable | 35.35 | 25.8 | 20.49 | -62.12 | 57.78 |
Change in Unearned Revenue | 12.33 | 4.8 | 13.31 | 0.18 | 4.58 |
Change in Other Net Operating Assets | -53.97 | -21.48 | -52.82 | 103.07 | -10.94 |
Operating Cash Flow | 319.48 | 348.04 | 415.13 | 277.48 | 336.5 |
Operating Cash Flow Growth | -8.21% | -16.16% | 49.60% | -17.54% | 52.81% |
Capital Expenditures | -63.56 | -60.21 | -91.9 | -584.27 | -61.67 |
Sale (Purchase) of Intangibles | -12.85 | -4.13 | -1.91 | -0.44 | - |
Investment in Securities | - | -20 | - | - | -273.84 |
Other Investing Activities | -0.41 | -0.19 | 0.12 | -0.33 | -0.57 |
Investing Cash Flow | -76.83 | -84.53 | -93.68 | -585.05 | -336.08 |
Short-Term Debt Issued | 250 | 250 | 280 | 660 | 50 |
Long-Term Debt Issued | - | - | 106.49 | 132 | 50 |
Total Debt Issued | 250 | 250 | 386.49 | 792 | 100 |
Short-Term Debt Repaid | -250 | -330 | -430 | -430 | -100 |
Long-Term Debt Repaid | -174.08 | -73.63 | -21.67 | -14.95 | -14.02 |
Total Debt Repaid | -424.08 | -403.63 | -451.67 | -444.95 | -114.02 |
Net Debt Issued (Repaid) | -174.08 | -153.63 | -65.17 | 347.06 | -14.02 |
Common Dividends Paid | -135.5 | -135.5 | -135.5 | -108.4 | -94.85 |
Other Financing Activities | 0.11 | 0.05 | 0.14 | 0.1 | - |
Financing Cash Flow | -309.47 | -289.09 | -200.54 | 238.75 | -108.88 |
Foreign Exchange Rate Adjustments | 0.34 | 0.62 | -0.08 | 0.06 | -0.16 |
Net Cash Flow | -66.47 | -24.96 | 120.84 | -68.75 | -108.62 |
Free Cash Flow | 255.92 | 287.83 | 323.23 | -306.79 | 274.83 |
Free Cash Flow Growth | -11.09% | -10.95% | - | - | - |
Free Cash Flow Margin | 11.98% | 14.29% | 17.59% | -15.89% | 18.68% |
Free Cash Flow Per Share | 9.43 | 10.61 | 11.91 | -11.31 | 10.13 |
Cash Interest Paid | 5.74 | 9.35 | 8.84 | 4.89 | 3.2 |
Cash Income Tax Paid | 62.83 | 86.68 | 75.3 | 60.15 | 28.87 |
Levered Free Cash Flow | 192.1 | 200.8 | 248.25 | -368.73 | 240.8 |
Unlevered Free Cash Flow | 195.63 | 206.6 | 253.78 | -365.56 | 242.8 |
Change in Working Capital | -63.94 | -14.36 | 72.99 | -158.11 | -3.02 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.